Company news
Vaccinex, Inc. news in 2026
Vaccinex, Inc.'s news releases, calls and decks from 2026, newest first.
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
October 7, 2026
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
July 8, 2026
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026